[HTML][HTML] The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R
Recent molecular studies indicate that aerobic glycolysis plays an important role in
tumorigenesis and is a valid target for cancer therapy. Although 2-deoxyglucose (2-DG) is
well characterized as a glycolytic inhibitor, we recently discovered that it activates a
prosurvival oncoprotein, AKT, through PI3K. In this study, we discovered that 2-DG
treatments disrupted the binding between insulin-like growth factor 1 (IGF-1) and IGF-
binding protein 3 (IGFBP3) so that the free form of IGF-1 could be released from the IGF-1 …
tumorigenesis and is a valid target for cancer therapy. Although 2-deoxyglucose (2-DG) is
well characterized as a glycolytic inhibitor, we recently discovered that it activates a
prosurvival oncoprotein, AKT, through PI3K. In this study, we discovered that 2-DG
treatments disrupted the binding between insulin-like growth factor 1 (IGF-1) and IGF-
binding protein 3 (IGFBP3) so that the free form of IGF-1 could be released from the IGF-1 …